AI drives new era of target identification and drug design

Disease modeling and target identification are critical and time-consuming portions of the drug discovery process and areas where artificial intelligence (AI) is already making a substantial impact. A new opinion paper in the Cell Press journal Trends in Pharmacological Sciences traces the history of target discovery methods - from experimental approaches, to multi-omics approaches, to machine learning and AI methods - and details how companies are using cutting-edge AI technologies to find targets and develop drugs now in Phase I and Phase II trials for diseases including cancer, Alzheimer's disease, diabetes, COVID-19, and idiopathic pulmonary fibrosis. Authors of the paper are experts at clinical stage AI drug discovery company Insilico Medicine.

Čítajte ďalej na https://www.pharmanews.eu/business/2944-ai-drives-new-era-of-target-identification-and-drug-design